Orion Corporation’s Financial Reporting Schedule for 2026
Orion Corporation is gearing up for an insightful year ahead with its financial reporting and Annual General Meeting set for 2026. This year marks a pivotal moment for investors and stakeholders who are keen on tracking the company's performance.
Key Reporting Dates for 2026
In 2026, Orion Corporation plans to unveil its Financial Statement Release for the fiscal year 2025 on February 12. This pivotal date serves as the starting point for several important reports that will follow throughout the year. Here’s what to anticipate:
- **Interim Report for January-March 2026:** Published on April 23.
- **Half-Year Financial Report for January-June 2026:** To be released on July 17.
- **Interim Report for January-September 2026:** Scheduled for publication on October 28.
These reports are crucial as they provide insights into the company's ongoing performance, strategic direction, and financial health.
Annual General Meeting Details
The Annual General Meeting is a significant event for Orion Corporation, slated to take place on March 24, 2026. This meeting offers an opportunity for shareholders to engage directly with the company, learn more about the financial outcomes of the past year, and discuss prospective strategies moving forward.
Availability of Financial Reports
Shareholders and interested parties can expect to find Orion's Financial Statements and the Board of Directors' report for 2025 available on their website by week 10 of 2026. This transparency reflects Orion's commitment to its stakeholders and showcases the company’s efforts in maintaining an open line of communication.
Access to Investor Resources
For those looking to stay updated with the latest information, Orion’s financial reports and accompanying presentation material will be readily available on their official investor relations website. This is a valuable resource for anyone who wants to delve deeper into the company's operations and strategic focus.
Additionally, Orion provides an option for individuals to register for mailing lists, ensuring they receive the latest updates and news releases directly.
The Orion Corporation Profile
Based in Finland, Orion Corporation is a prominent global player in the pharmaceutical sector, acknowledged for building well-being over the past century. The company specializes in developing, manufacturing, and marketing both human and veterinary pharmaceuticals, alongside active pharmaceutical ingredients.
With a diverse portfolio that includes both proprietary and generic products, Orion addresses various health needs, particularly focusing on core areas such as oncology and pain management. Their proprietary treatments cater to serious conditions such as cancer, neurological disorders, and respiratory ailments.
As of 2024, Orion reported net sales of approximately EUR 1,542 million and employs around 3,700 dedicated professionals striving to improve health and well-being worldwide. Moreover, Orion’s A and B shares are listed on Nasdaq Helsinki, symbolizing their commitment to transparency and shareholder value.
Contact Information
For any inquiries, investors may reach out directly to Tuukka Hirvonen, the Head of Investor Relations. He's available at +358 10 426 2721. This direct line allows stakeholders to engage in meaningful dialogue regarding their investments and any questions they may have.
Frequently Asked Questions
1. When is the first financial report for 2026 due?
The first financial report is the Financial Statement Release for 2025, scheduled for February 12, 2026.
2. What is the date of the Annual General Meeting?
The Annual General Meeting is planned for March 24, 2026.
3. Where can I find Orion Corporation's financial reports?
Financial reports will be available on Orion Corporation's official website, particularly in the investor relations section.
4. How can I stay updated on Orion's releases?
You can register on Orion's mailing lists provided on their website to receive the latest news and updates directly.
5. What focus areas does Orion Corporation prioritize in its R&D?
Orion primarily focuses on oncology and pain management in its pharmaceutical research and development efforts.
